RBA Wealth Management LLC Acquires New Holdings in Becton, Dickinson and Company (NYSE:BDX)

RBA Wealth Management LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 20,727 shares of the medical instruments supplier’s stock, valued at approximately $4,997,000. Becton, Dickinson and Company makes up 1.9% of RBA Wealth Management LLC’s holdings, making the stock its 22nd biggest holding.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. WR Wealth Planners LLC lifted its position in shares of Becton, Dickinson and Company by 1.4% in the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after purchasing an additional 42 shares in the last quarter. Key Client Fiduciary Advisors LLC grew its stake in shares of Becton, Dickinson and Company by 2.6% in the first quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock valued at $424,000 after acquiring an additional 43 shares in the last quarter. Clear Creek Financial Management LLC grew its stake in shares of Becton, Dickinson and Company by 5.1% in the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after acquiring an additional 44 shares in the last quarter. Sound Income Strategies LLC grew its stake in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Finally, Central Pacific Bank Trust Division lifted its holdings in shares of Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 45 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.3 %

Shares of NYSE BDX traded down $0.70 during trading on Tuesday, reaching $239.82. The stock had a trading volume of 429,259 shares, compared to its average volume of 1,385,380. The company has a market cap of $69.31 billion, a P/E ratio of 52.96, a PEG ratio of 1.79 and a beta of 0.42. The business’s 50-day moving average price is $237.14 and its 200-day moving average price is $235.16. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $262.23. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter in the previous year, the firm posted $2.96 EPS. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, equities research analysts predict that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Raymond James lowered their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus lifted their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Buy” and a consensus price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.